Dulaglutide

Development and Structure

Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly GLP-1 receptor agonist approved by the FDA in September 2014 for type 2 diabetes. Structurally, it differs from the other approved GLP-1 agonists in an important way: it is not a simple lipidated peptide but a Fc-fusion protein. Two modified GLP-1 analogue chains (each with substitutions at DPP-4-cleavage sites) are covalently linked via flexible peptide linkers to the Fc region of human immunoglobulin G4 (IgG4).

The IgG4 Fc scaffold accomplishes the same pharmacokinetic goal that albumin-binding fatty acids achieve in semaglutide and liraglutide — prolonged plasma half-life — but via FcRn-mediated recycling rather than albumin association. The resulting half-life is approximately 5 days, supporting once-weekly subcutaneous dosing. The larger molecular size (~63 kDa versus ~4 kDa for semaglutide) also means dulaglutide does not readily cross into tissues the way smaller analogues can.

Mechanism

Pharmacodynamically, dulaglutide produces the standard GLP-1 class effects — glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and central appetite modulation. The functional differences from other class members stem from the Fc-fusion architecture: the large molecular size may produce slightly less CNS penetration per unit of circulating drug, which some pharmacologists have cited as a possible reason for dulaglutide's somewhat smaller weight-loss magnitude compared to semaglutide at its highest doses.

Clinical Evidence

The dulaglutide evidence base was established by the AWARD program — a series of Phase 3 trials (AWARD-1 through AWARD-11) evaluating dulaglutide across the T2D treatment spectrum. Highlights:

• AWARD-1 through -6. Established HbA1c reductions of ~1.0–1.6 percentage points across various combination regimens, and head-to-head non-inferiority or superiority versus exenatide, liraglutide, sitagliptin, and insulin glargine.
• REWIND (2019). The dedicated cardiovascular outcomes trial in 9,901 T2D patients — notably, the majority without established cardiovascular disease. REWIND reported a 12% reduction in major adverse cardiovascular events, making dulaglutide one of the first GLP-1 agents to show CV benefit in a primary-prevention-enriched population. A pre-specified analysis also reported meaningful stroke reduction.
• AWARD-11 (2020). Established the higher-dose 3.0 mg and 4.5 mg formulations, which produced incremental HbA1c and weight-loss benefit versus the 1.5 mg standard dose.

Where Dulaglutide Fits

Dulaglutide's clinical niche is defined by three strengths: ease of use (the pre-filled pen does not require reconstitution or dose titration from a starting dose — it is administered at full dose from week one); REWIND's CV evidence in a lower-risk population, which supports its use earlier in the T2D disease course; and a well-established long-term safety record going back over a decade.

Its limitations are that weight-loss magnitude is modest compared to semaglutide or tirzepatide, and it has no approved obesity indication — Lilly's obesity portfolio is built around tirzepatide and retatrutide, not dulaglutide.

Safety

Adverse-event profile is class-typical — gastrointestinal symptoms dominant, concentrated early after initiation or dose escalation. Injection-site reactions are less common than with lipidated small-peptide analogues, likely reflecting the Fc-fusion architecture. Pancreatitis and gallbladder events occur at class-typical rates. The FDA label carries the boxed warning for rodent thyroid C-cell tumors with contraindications in MEN2 syndrome and personal or family history of medullary thyroid carcinoma.

The Bottom Line

Dulaglutide is a durable, well-evidenced, easy-to-administer weekly GLP-1 agent that is most useful for T2D glycemic control and CV risk reduction rather than for weight loss. In the hierarchy of current GLP-1 agents, it sits below semaglutide on pure efficacy but often above it on practical administration. For a broader look at how the class is evolving toward multi-receptor and oral therapies, see our 2026 oral GLP-1 overview.